HUNTINGTON BEACH, CA – June 4, 2026 – Leonhardt Ventures LLC announced today a new provisional patent application covering methods and systems for the use of targeted bioelectric stimulation of bone to increase expression and release of osteocalcin, a hormone produced by bone that has been linked to numerous health benefits including cognitive function, sexual health, metabolic health, muscle performance, and healthy aging.
The technology has been exclusively licensed to Lionheart Health, Inc. for commercialization through its growing portfolio of bioelectric healthspan and regenerative medicine programs.
Osteocalcin has emerged as one of the most intriguing signaling molecules in the body. Produced primarily by osteoblasts within bone, osteocalcin acts as an endocrine hormone influencing multiple organ systems. Scientific studies have associated osteocalcin with memory formation, learning, mood regulation, testosterone production, fertility, glucose metabolism, insulin sensitivity, muscle performance, exercise capacity, and healthy aging.
The Leonhardt Ventures provisional patent application covers the use of specific bioelectric signaling patterns, waveforms, frequencies, pulse durations, and stimulation protocols designed to activate bone tissue and enhance endogenous osteocalcin production without the need for drugs or gene therapies.
“Bone is increasingly recognized as an endocrine organ that communicates with the brain, reproductive organs, muscles, and metabolic systems,” said Howard J. Leonhardt, Executive Chairman and Co-CEO of Lionheart Health and Managing Member of Leonhardt Ventures LLC. “Our goal is to harness the body’s own biology by using precisely controlled bioelectric signals to encourage bone to produce higher levels of osteocalcin and potentially improve multiple dimensions of health simultaneously.”
Potential applications under investigation include:
• Cognitive health and memory support
• Brain performance and neuroprotection
• Healthy testosterone production
• Sexual wellness and reproductive health
• Insulin sensitivity and glucose control
• Exercise performance and muscle function
• Bone health and skeletal integrity
• Healthy aging and healthspan enhancement
• Recovery and rehabilitation programs
• Longevity-focused wellness protocols
The provisional patent application expands Leonhardt Ventures’ growing intellectual property portfolio focused on bioelectric control of naturally occurring proteins, growth factors, hormones, and regenerative signaling pathways. The company has previously filed patent applications related to bioelectric stimulation of Klotho, BDNF, Sirtuins, Menin, GDF10, GDF11, Sonic Hedgehog, and numerous other healthspan-associated factors.
Lionheart Health plans to evaluate osteocalcin-focused stimulation protocols through future clinical studies and wellness programs as part of its broader mission to increase healthy lifespan and improve quality of life through bioelectric medicine.
The company believes osteocalcin may represent another important target in the emerging field of healthspan optimization, complementing its ongoing research involving Klotho, BDNF, Sirtuins, and other longevity-associated biological pathways.
About Leonhardt Ventures LLC
Founded in 1982, Leonhardt Ventures LLC is a medical innovation company focused on developing breakthrough technologies in bioelectric medicine, regenerative medicine, cardiovascular care, healthy aging, and longevity. The company and its affiliated ventures have developed hundreds of patent claims and multiple FDA-cleared technologies spanning several decades.
About Lionheart Health, Inc.
Lionheart Health, Inc. is focused on extending healthspan and improving quality of life through bioelectric stimulation, enhanced biologics, regenerative medicine, and longevity-focused health optimization programs. The company is a semifinalist in the XPRIZE Healthspan competition and is advancing multiple technologies designed to increase the body’s natural production of beneficial healthspan-associated proteins and signaling molecules.
Media Contact:
Howard J. Leonhardt
Executive Chairman & Co-CEO
Lionheart Health, Inc.
Managing Member
Leonhardt Ventures LLC
Forward-Looking Statements
This press release contains forward-looking statements regarding research, development, intellectual property, and potential health applications. These statements are based on current expectations and involve risks and uncertainties. The described technology is currently the subject of a provisional patent application and has not been evaluated by the U.S. Food and Drug Administration for the diagnosis, treatment, cure, or prevention of any disease. Future clinical studies will be required to evaluate safety and effectiveness.
Selected Scientific References on Osteocalcin
- Gerard Karsenty et al. Research establishing bone as an endocrine organ and osteocalcin as a hormone influencing metabolism and reproduction.
- Franck Oury et al. Demonstrated osteocalcin’s role in memory, cognition, anxiety, and brain development.
- Endocrinology studies showing osteocalcin regulation of insulin secretion and insulin sensitivity.
- Neuroscience studies linking osteocalcin levels with cognitive performance and age-related brain function.
- Osteocalcin research demonstrating effects on testosterone synthesis and male fertility in animal models.
- Geroscience investigations associating declining osteocalcin levels with age-related functional decline and reduced physical performance.